Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib and Azacitidine in MDS
NCT07387354Phase 2Withdrawn
- Sponsor
- Thomas Jefferson University
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of pacritinib in myelodysplastic syndrome (MDS), sponsored by Thomas Jefferson University. Planned start Sep 2026; status: withdrawn.
02
Drugs
pacritinib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07387354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07387354.